Phaseline

Companies › T3 Pharmaceuticals

T3 Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
T3P-Y058-739
Genetically-modified, live attenuated Yersinia enterocolitica strain
–Phase 1Advanced Solid TumorFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05120596T3P-Y058-739Phase 1Advanced Solid TumorOncologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.